Innovate Biopharmaceuticals, Inc. (INNT): Price and Financial Metrics


Innovate Biopharmaceuticals, Inc. (INNT)

Today's Latest Price: $1.10 USD

0.01 (-0.90%)

Updated Oct 15 8:00pm

Add INNT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 329 in Biotech

See all "A" rated Strong Buy stocks

INNT Daily Price Range
INNT 52-Week Price Range

INNT Stock Price Chart More Charts


INNT Price/Volume Stats

Current price $1.10
Prev. close $1.11
Day low $1.05
Day high $1.13
50-day MA $0.98
200-day MA $1.52
52-week high $5.49
52-week low $0.73
Volume 117,700
Avg. volume 460,867
Dividend yield N/A
Market Cap 39.47M

Innovate Biopharmaceuticals, Inc. (INNT) Company Bio


Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics. Its late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease (IBD), and nonalcoholic steatohepatitis (NASH). The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease. It is also developing INN-108, which is entering into Phase 2 clinical trials for the treatment of mild to moderate ulcerative colitis. In addition, the company owns the global rights to INN-329, a proprietary formulation of secretin, a peptide hormone used to enhance visualization in magnetic resonance cholangiopancreatography procedures. Innovate Biopharmaceuticals, Inc. was founded in 2012 and is based in Raleigh, North Carolina.





INNT Latest News Stream


Event/Time News Detail
Loading, please wait...

INNT Latest Social Stream


Loading social stream, please wait...

View Full INNT Social Stream

INNT Price Returns

1-mo -5.98%
3-mo 0.00%
6-mo -36.42%
1-year -79.44%
3-year -92.41%
5-year N/A
YTD -52.38%
2018 -62.13%
2017 -65.14%
2016 N/A
2015 N/A
2014 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.3804 seconds.